Astellas has been announced as Pharmaceutical Company of the Year at the 9th Annual SCRIP Awards. The accolade recognises outstanding achievement by a pharmaceutical company, spanning all aspects of the business, including commercial success and pipeline development. The SCRIP Awards initiative salutes innovation and excellence across the international biopharmaceutical sector and is amongst the most prestigious in the industry.
From November 20th to 22nd the first edition of the Medical Delta ECE Innovation Challenge was held at the Rotterdam Science Incubator. The challenge is created by the Erasmus Centre for Entrepreneurship in order to give young students the exiting opportunity to sample the thrills of becoming young entrepreneurs. During a 3-day boot camp motivated and creative teams were asked to develop a solution to a challenging question, presented by the VITALITY! Programme of Medical Delta: How can we encourage and assist the older generation to get the most out of life, and continue to make a contribution to society, despite disabilities?
VitalneXt BV and Acacia Soluciones (La Nucia, Alicante, Spain) announced that they have concluded an exclusive distribution agreement under which Acacia will promote and sell Promanna™ in Spain. Promanna™ is a nutritional supplement in the field of ‘Healthy Ageing’ and has been developed by Vitalnext. It was first launched in The Netherlands two months ago where it is
marketed and sold by Nutramin BV.
Prosensa Holding N.V., the Dutch biopharmaceutical company focusing on rare diseases with a high unmet medical need, and Newcastle University, UK, have announced the award of a second Framework Programme 7 (FP7) research grant from the European Union. This new FP7 research grant totals approximately EUR 6 million to support the development of imaging biomarkers for Duchenne muscular dystrophy (DMD).
An international consortium of scientists, led by the University Lund, Sweden, has launched a EUR 12 million EU-funded collaboration project focused on identifying novel biomarkers for epileptogenesis and exploring new ways of how to treat epilepsy, with the project acronym EPITARGET. The EPITARGET consortium consists of 13 renowned academic institutions and 4 specialized, innovative SMEs. The Dutch biotech to-BBB will receive substantial funding for its involvement in this ambitious 5-year project.
Welch Allyn, a leading medical diagnostic device company that specializes in helping clinicians improve patient safety and outcomes, announced the official establishment of its Europe, Middle East & Indian Sub-Continent (EMEI) headquarters and a consolidated Operations Center in the Netherlands. Both sites are part of the company's current realignment strategy aimed at positioning Welch Allyn for future growth throughout the region.
The BioBusiness Masterclass starts in February 2014. The Masterclass is the course for entrepreneurs in life sciences, agri-food and chemistry. If you want to progress to a management position with your current employer or might want to start your own business in your career you should definitely participate. The Masterclass will start in February and will run for nine months.
> Read more in Dutch
ZoBio announced a collaboration with Actelion Pharmaceuticals Ltd to discover conformationally selective fragment ligands for one of Actelion’s oncology targets. Under the agreement, ZoBio will apply its proprietary TINS technology to screen a library of drug fragments for specific binding to the desired conformation of the target.
ISA Pharmaceuticals B.V., a clinical-stage biopharmaceutical company focusing on rationally designed therapeutic vaccines against cancer and persistent viral infections, announced the initiation of a Phase I/II clinical study of its lead candidate ISA101 in women with HPV16-positive advanced or recurrent cervical cancer, eligible for standard chemotherapy with carboplatin and paclitaxel (CervISA study). The first patient was vaccinated this month.
Commercialization of the quality research taking place in Leiden is a key priority of both Leiden University and Leiden University Medical Center (LUMC). Not only is the research activity itself strengthened, but also the output can be effectively utilized by society for economic and clinical benefit. The role of LURIS is to facilitate this commercialization process for the University and the LUMC.
BabyBloom Healthcare from Leidenhas been recognised as a potential business giant of the future in a newly launched Europe-wide business initiative called ‘They Could Be Giants’.
Created by the European Business Awards, ‘They Could be Giants’ has been set up to showcase and monitor companies with a ground-breaking product or service that have the proven potential to revolutionise the market in their field.
During the Dutch Life Sciences Conference on the 9th of December in Oss, HollandBIO will host the Investors Forum. The Investors Forum is an exciting event for companies looking for equity capital and/or partnerships. The winner of the Investors Forum will be awarded a partnering ticket with a total value of EUR 2,500.00
The Leiden Bio Science Park newsletter is a free bimonthly email newsletter in English. The newsletter offers general life science news, news from the companies and institutions, a company profile, events and jobs.
click here to subscribe